Bone Biologics Corp (BBLG) Financial Statements (2024 and earlier)

Company Profile

Business Address 2 BURLINGTON WOODS DRIVE,
BURLINGTON, MA 01803
State of Incorp. DE
Fiscal Year End December 31
Industry (SIC) 3842 - Orthopedic, Prosthetic, and Surgical Appliances and Supplies (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in millions)

9/30/2023
MRQ
12/31/2022
12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments87 011
Cash and cash equivalents87 011
Prepaid expense1  000
Total current assets:87 011
Noncurrent Assets
Property, plant and equipment     00
Total noncurrent assets:     00
TOTAL ASSETS:87 011
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities, including:100001
Employee-related liabilities  001
Accounts payable   0000
Other undisclosed accounts payable and accrued liabilities10    
Debt   0   
Deferred compensation liability   0000
Due to related parties  12 9 
Other undisclosed current liabilities2 10  
Total current liabilities:30141101
Noncurrent Liabilities
Liabilities, other than long-term debt    11 8
Due to related parties   11 8
Total noncurrent liabilities:    11 8
Total liabilities:301412109
Equity
Equity, attributable to parent67(14)(12)(9)(8)
Common stock000000
Common stock, share subscribed but unissued, subscriptions receivable      2
Additional paid in capital787755555549
Accumulated deficit(72)(70)(69)(67)(64)(59)
Total equity:67(14)(12)(9)(8)
TOTAL LIABILITIES AND EQUITY:87 011

Income Statement (P&L) ($ in millions)

9/30/2023
TTM
12/31/2022
12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
Revenues   1,0701,070  
Gross profit:   1,0701,070  
Operating expenses(4)(1)(1)(2)(3)(3)
Other undisclosed operating loss   (1,070)(1,070)  
Operating loss:(4)(1)(1)(2)(3)(3)
Nonoperating income (expense) 2(1) (1)(2)(4)
Interest and debt expense  (1)(1)(1)(0)(0)
Other undisclosed income from continuing operations before equity method investments, income taxes     0
Loss from continuing operations before equity method investments, income taxes:(1)(2)(2)(4)(4)(7)
Other undisclosed income from continuing operations before income taxes  1 10 
Loss from continuing operations before income taxes:(1)(2)(2)(3)(4)(7)
Income tax expense  (0)(0)(0)(0)(0)
Other undisclosed income from continuing operations      
Loss from continuing operations:(1)(2)(2)(3)(4)(7)
Loss before gain (loss) on sale of properties:(2)(2)(3)(4)(7)
Net loss:(1)(2)(2)(3)(4)(7)
Other undisclosed net income attributable to parent      
Net loss available to common stockholders, diluted:(1)(2)(2)(3)(4)(7)

Comprehensive Income ($ in millions)

9/30/2023
TTM
12/31/2022
12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
Net loss:(1)(2)(2)(3)(4)(7)
Comprehensive loss, net of tax, attributable to parent:(1)(2)(2)(3)(4)(7)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: